IP Library Granted Patent US 8,008,440
Granted Patent B2
US 8,008,440 · App. 11/615,332 · Granted Aug 30, 2011

Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,008,440
App. No.
11/615,332
Granted
Aug 30, 2011
Kind
B2
Abstract

A library of macrocyclic compounds of the formula (I) where part (A) is a bivalent radical, a —(CH 2 ) y — bivalent radical or a covalent bond; where part (B) is a bivalent radical, a —(CH 2 ) z — bivalent radical, or a covalent bond; where part (C) is a bivalent radical, a —(CH 2 ) t — bivalent radical, or a covalent bond; and where part (T) is a —Y-L-Z- radical wherein Y is CH 2 or CO, Z is NH or O and L is a bivalent radical. These compounds are useful for carrying out screening assays or as intermediates for the synthesis of other compounds of pharmaceutical interest. A process for the preparation of these compounds in a combinatorial manner, is also disclosed.

Claims (28)

1. A macrocyclic compound of formula I:

and pharmaceutically acceptable salts thereof, wherein A 1 is

where the nitrogen is bonded to T and the carbonyl is bonded to A 2 ;

X is 0, 1 or 2;

R 1 is selected from the group consisting of:

wherein (P) indicates the point of attachment to CH;

W 1 to W 16 are each independently hydrogen or a protecting group used for orthogonal protection in peptide synthesis; and

X is selected from the group consisting of:

A 2 is selected from the group consisting of prolinyl, 4-hydroxyprolinyl, 4-tert-butoxyprolinyl; and

where the nitrogen is bonded to the carbonyl of A 1 and the carbonyl is bonded to A 3 ; wherein

y is 0, 1 or 2;

R 2 is selected from the group consisting of:

wherein (P) indicates the point of attachment to CH; and

W 1 to W 16 are each independently hydrogen or a protecting group used for orthogonal protection in peptide synthesis;

A 3 is selected from the group consisting of prolinyl, 4-hydroxyprolinyl, 4-tert-butoxyprolinyl; and

where the nitrogen is bonded to the carbonyl of A 2 and the carbonyl is bonded to T; wherein

z is 0, 1 or 2;

R 3 is selected from the group consisting of:

wherein (P) indicates the point of attachment to CH; and

W 1 to W 16 are each independently hydrogen or a protecting group used for orthogonal protection in peptide synthesis; and

(T) is selected from the group consisting of:

wherein (A 3 ) indicates the site of a covalent bond to A 3 of formula I and (A 1 ) indicates the site of a covalent bond to A 1 of formula I;

M is selected from the group consisting of —O—, —S—, —NH—, and —N(CH 3 )—;

R 10 and R 11 are independently —H or —CH 3 ; and

n1, n2, n3, n4, n5, n6 and n7 are independently 1 or 2;

with the proviso that compounds wherein R 1 is —(CH 2 ) 3 —NW 3 —C(═NW 2 )—NHW 1 , R 2 is —H and R 3 is —CH 2 CO 2 W 5 are excluded.

2. The macrocyclic compound of claim 1 , wherein T is selected from the group consisting of:

wherein (A 3 ) indicates the site of a covalent bond to A 3 of formula I and (A 1 ) indicates the site of a covalent bond to A 1 of formula I.

Assignments (2)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 044949, FRAME 0634 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0460 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Dec 22, 2017
From: OCERA THERAPEUTICS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 044949/0634 →